- Source type
- Study
- Access type
- Abstract/index
- Publisher
- JAMA
- Indexed by
- PubMed
- Date
- 2021
- Added
- 2026-06-19
Trust profile
91
Government health research
- Publisher type
- Government research
- Bias profile
- Low
Best used for
- Research synthesis
- Public-health context
- Safety resources
Weak for
- Primary endpoint extraction when a study is available
Used in Viral Vitalism
GLP-1s Are Not Just a Weight Loss Story
Roles: Primary source
Show section-level references
Effect of continued weekly semaglutide vs placebo on weight loss maintenance
Roles: Primary source
Show section-level references
Claims supported
- Weight maintenance commonly depends on continued treatment, while optimal long-term strategies and lean-mass preservation remain active evidence gaps.
- Cost, access, adherence, tolerability, and long-term maintenance materially affect the real-world value of GLP-1 therapy.
Related studies
Related sources
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder
Trial registry for oral semaglutide among adults with AUD.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
Does Semaglutide Reduce Alcohol Intake
Trial registry for semaglutide and alcohol intake.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
Effects of Semaglutide on Nicotine Intake
Trial registry for semaglutide and nicotine intake.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 2 connections
ESSENCE clinical trial registry
ClinicalTrials.gov used across the Viral Vitalism evidence library.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 3 connections
ESSENCE phase 3 trial design for semaglutide in MASH
PubMed used across the Viral Vitalism evidence library.
- Trust score
- 91
- Publisher
- PubMed
- Indexed by
- PubMed
- Access
- Abstract/index
- Usage
- 2 connections
GLP-1R Agonist Treatment for Opioid Use Disorder
Trial registry testing whether semaglutide can reduce illicit opioid use in adults in outpatient OUD treatment.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
